Aralez Bio – January 2025
Aralez Bio is a platform technology company revolutionizing the synthesis of noncanonical amino acids, ncAAs, through biocatalysis. Their proprietary processes enable the production of thousands of ncAAs sustainably at production scales. Founded in 2019 Aralez Bio has rapidly advanced in the biotech industry. In December 2024, the company secured Series A funding and in 2025 moved to a facility in Berkeley, CA, capable of ton-scale production. Aralez Bio's extensive collection of novel ncAAs provides unparalleled atomic-level control in peptide medicinal chemistry, empowering the development of next-generation therapeutics. Their commitment to sustainability and innovation positions us at the forefront of modern drug discovery and development.
Stay tuned for more exciting features, and don’t miss the chance to get your lab featured!
Please contact Lars Sahl to get involved!
Peptide Purification
In this sponsored content by Gyros Protein Technologies, learn how to remove impurities faster with less solvent consumption using catch-and-release technology.
Peptide-related impurities can significantly influence the outcome of drug research and development, for example, false-positive results, and must be removed to ensure high assay reliability.
Ultimately, such impurities must be removed entirely from active pharmaceutical ingredients to provide the highest quality clinical-grade material. This article tells you how.
What Current Members Say
The American Peptide Society has for many years been central to advancing and promoting peptide research through activities such as regular symposiums, the Peptide Science Journal, and ongoing webinars and news highlights. These efforts are an essential contribution to the field which benefits both the academic and industrial communities.
Jon Collins
Director of Business Development
CEM
"The American Peptide Society is at the forefront of showcasing innovative research and emerging trends in the field. The symposiums are a combination of inspiration and knowledge, essential for all peptide enthusiasts in academia and pharma to stay ahead in peptide science."
Danny Chou
Assistant Professor of Pediatrics Endocrinology
Stanford University, School of Medicine
“Being a member of the American Peptide Society and attending the Peptide Symposium, one of the key asset of the society, I have gain new perspectives on emerging peptide technologies, and gain insights about current challenges from prominent peptide leaders. It is a great society for the education and professional development for our peptide scientist.”
Ved Srivastava
Ph.D., Vice President of Peptide Chemistry
Intarcia Therapeutics